A 2012 law that loosened conflict-of-interest restrictions for FDA advisory panels could weaken the agency’s review system and could allow more drugs with safety problems to gain market approval, says a new analysis.
A 2012 law that loosened conflict-of-interest restrictions for FDA advisory panels could weaken the agency’s review system and could allow more drugs with safety problems to gain market approval, says a new analysis.